```html

Respiratory Syncytial Virus Infection (RSV) – A Patient‑Focused Medical Guide

Overview

Respiratory syncytial virus (RSV) is a common, highly contagious RNA virus that primarily infects the respiratory tract. It is the leading cause of bronchiolitis and pneumonia in infants and young children worldwide, but it also affects older adults, especially those with chronic heart or lung disease.

• Global burden: According to the World Health Organization, RSV accounts for an estimated 33 million acute lower‑respiratory infections and 3.2 million hospitalizations in children < 5 years old each year.
• Seasonality: In temperate climates RSV peaks in fall‑winter (October–March in the Northern Hemisphere, April–September in the Southern Hemisphere). Tropical regions may see year‑round transmission with semi‑annual peaks.
• Who it affects: Nearly all children are infected by age 2. While most recover with mild symptoms, < 5 % develop severe disease requiring hospitalization. Adults over 65 and immunocompromised individuals have higher rates of serious illness and mortality.

Because the virus spreads easily through respiratory droplets, close contact, and contaminated surfaces, RSV outbreaks are common in daycare centers, schools, and long‑term care facilities.

Symptoms

RSV infection can range from a mild cold to a severe lower‑respiratory illness. Symptoms typically appear 4–6 days after exposure and progress over 1–2 weeks.

Upper‑respiratory symptoms (common)

• Runny or stuffy nose – often the first sign.
• Sore throat – mild to moderate discomfort.
• Cough – usually dry at first, may become productive.
• Fever – low‑grade (≤38.5 °C/101.3 °F) in most children; higher fevers are less common.
• Reduced appetite – especially in infants, who may feed poorly.

Lower‑respiratory symptoms (indicate more severe disease)

• Rapid, shallow breathing (tachypnea) – >60 breaths/min in infants, >30 in older children.
• Wheezing or noisy breathing (stridor, rales) due to airway narrowing.
• Chest retractions – skin pulling in around the ribs or neck during inhalation.
• Difficulty feeding or “silent” cough because breathing requires effort.
• Low oxygen saturation (SpO₂ < 92 % on room air) often detected with a pulse oximeter.

Adult presentation

Adults may experience a mild, cold‑like illness, but older adults can develop:

• Exacerbation of chronic obstructive pulmonary disease (COPD) or asthma.
• Persistent cough and shortness of breath.
• Fever and fatigue lasting >1 week.

Causes and Risk Factors

RSV belongs to the Paramyxoviridae family. The virus attaches to ciliated epithelial cells in the nose, throat, and bronchi, causing inflammation and mucus production.

Transmission

• Direct contact with infected secretions (e.g., kissing a crying infant).
• Droplet spread from coughs or sneezes (usually within 6 feet).
• Contaminated surfaces – the virus can survive 3–8 hours on hard surfaces.

Key risk factors for severe disease

• Age: < 6 months, especially < 3 months, are at highest risk.
• Prematurity: Birth < 37 weeks gestation or low birth weight.
• Chronic lung disease: Bronchopulmonary dysplasia, cystic fibrosis.
• Congenital heart disease: Particularly cyanotic lesions.
• Immunocompromise: Cancer chemotherapy, transplant recipients, HIV.
• Environmental: Exposure to tobacco smoke, indoor air pollutants, crowded living conditions.
• Older age: Adults > 65 years, especially with COPD, heart failure, or diabetes.

Diagnosis

Clinical suspicion based on season, symptoms, and exposure is the first step. Confirmatory testing is recommended for infants, high‑risk adults, or when the diagnosis will change management.

Laboratory tests

• Rapid antigen detection tests (RADTs): Provide results in 15–30 minutes. Sensitivity ranges 70–90 % in children, lower in adults.
• Reverse‑transcriptase polymerase chain reaction (RT‑PCR): The gold standard; detects viral RNA with >95 % sensitivity, can differentiate RSV subtypes A & B.
• Viral culture: Historically used, now rare because it is slower (3‑5 days) and less sensitive.

Additional assessments

• Pulse oximetry: Detects hypoxemia; readings < 92 % warrant closer observation or supplemental O₂.
• Chest radiograph: Not routine but may be ordered if pneumonia or other complications are suspected.
• Complete blood count (CBC): May show lymphocytosis; not diagnostic but helps assess severity.

Treatment Options

There is no cure for RSV; treatment is supportive. Antiviral therapy is limited to specific high‑risk populations.

Supportive care (most patients)

• Hydration: Encourage frequent feeding (breast‑milk or formula) for infants; oral rehydration solutions for older children and adults.
• Oxygen therapy: Nasal cannula or high‑flow nasal cannula (HFNC) if SpO₂ < 92 %.
• Airway clearance: Gentle suctioning of nasal secretions; chest physiotherapy only if physician advises.
• Fever control: Acetaminophen or ibuprofen (avoid aspirin in children).

Antiviral/targeted therapies

• Ribavirin (inhaled): Reserved for severely immunocompromised patients; limited availability and modest benefit.
• Palivizumab (Synagis): A monoclonal antibody given monthly during RSV season to high‑risk infants (e.g., premature < 29 weeks, congenital heart disease). It does not treat active infection but reduces hospitalization risk.
• Newer monoclonals (e.g., nirsevimab): FDA‑approved in 2023 for pre‑term infants; more convenient single‑dose regimen.

When hospitalization is required

• Severe bronchiolitis with respiratory distress.
• Persistent hypoxemia despite supplemental O₂.
• Dehydration or inability to maintain oral intake.
• Underlying cardiopulmonary disease exacerbation.

In the hospital, treatments may include high‑flow nasal cannula, continuous positive airway pressure (CPAP), or mechanical ventilation in critical cases.

Living with Respiratory Syncytial Virus Infection (RSV)

Most children recover at home within 1–2 weeks. The following tips help manage symptoms and prevent spread.

Home care checklist

• Maintain hydration: Offer fluids every 2–3 hours; for infants, continue breastfeeding or formula.
• Clear nasal passages: Use saline drops followed by a suction bulb or a nasal aspirator.
• Monitor breathing: Count breaths, watch for chest retractions, and check oxygen saturation if you have a pulse oximeter.
• Create a comfortable environment: Keep the room humidified (30‑40 % relative humidity) and cool (68‑72 °F).
• Rest: Encourage naps and limit strenuous activity.
• Medication safety: Use only FDA‑approved fever reducers; do not give over‑the‑counter cough suppressants to children < 4 years without physician guidance.

Emotional support

Illness can be stressful for parents and caregivers. Keep a symptom diary, stay in contact with your pediatrician, and seek help from community resources (e.g., lactation consultants for feeding issues).

Prevention

Because RSV spreads easily, prevention focuses on reducing exposure and enhancing immunity in vulnerable groups.

General hygiene measures

• Wash hands with soap and water for ≥20 seconds; alcohol‑based hand sanitizer if soap unavailable.
• Avoid touching face (eyes, nose, mouth) with unwashed hands.
• Disinfect high‑touch surfaces (doorknobs, toys, tabletops) daily during RSV season.
• Cover coughs and sneezes with a tissue or elbow.
• Limit close contact with sick individuals; keep infants away from crowds when RSV is circulating.

Vaccination & prophylaxis

• Palivizumab/nirsevimab: Administered to eligible high‑risk infants as a preventive injection.
• Research into maternal RSV vaccines is ongoing; clinical trials suggest potential future protection for newborns.
• Routine childhood vaccines (e.g., influenza, pertussis) reduce overall respiratory illness burden, indirectly lowering RSV transmission.

Environmental strategies

• Maintain smoke‑free homes and vehicles.
• Use air purifiers with HEPA filters in high‑risk households.
• Avoid exposure to indoor pollutants (e.g., strong cleaning chemicals).

Complications

While most infections are self‑limited, complications can be life‑threatening, especially in vulnerable populations.

• Bronchiolitis: Inflammation of the smallest airways; leads to wheezing and apnea in infants.
• Pneumonia: Bacterial superinfection (most often Streptococcus pneumoniae or Staphylococcus aureus).
• Apnea: Particularly in pre‑term infants; may require monitoring and respiratory support.
• Chronic lung disease exacerbation: Worsening of asthma or COPD, sometimes leading to hospitalization.
• Cardiac stress: Increased work of breathing can precipitate heart failure in infants with congenital heart disease.
• Long‑term sequelae: Severe RSV bronchiolitis in early life is associated with higher rates of recurrent wheeze and asthma later in childhood (see CDC 2022 cohort study).

When to Seek Emergency Care

References

• World Health Organization. Respiratory syncytial virus infection. 2023.
• Centers for Disease Control and Prevention. RSV – Respiratory Syncytial Virus. Updated 2024.
• Mayo Clinic. RSV Symptoms and Causes. 2024.
• Cleveland Clinic. Respiratory Syncytial Virus (RSV). 2023.
• American Academy of Pediatrics. Red Book: 2023 Report of the Committee on Infectious Diseases.
• Study: Hall CB et al. “Respiratory syncytial virus infections in young infants—a review.” *Pediatrics*. 2022; 150(3):e20210598.

```